{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:29Z","timestamp":1787027009384,"version":"build-2736575974"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Tic disorders (TD) are common childhood neurodevelopmental conditions, characterized by diverse manifestations, leading to misdiagnosis and delayed therapy. Timely identification of TD and access to care can improve clinical outcomes. This retrospective study characterizes clinical features and initial pharmacotherapy in newly diagnosed pediatric TD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This retrospective cohort study included 805 newly diagnosed pediatric TD patients. Tic severity was assessed using the Yale Global Tic Severity Scale (YGTSS), with patients stratified into mild (YGTSS scores\u2009&amp;lt;\u200925), moderate (25\u201350), and severe (&amp;gt;50) groups. Chi-square tests\/Fisher-exact tests and Wilcoxon rank\u2014sum tests compared group differences in baseline characteristics. Multivariate analyses identified factors associated with tic severity, and logistic regression analyses identified predictors of pharmacotherapy initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 805 subjects, 73.43%, 11.18% and 15.39% were classified into provisional tic disorder, chronic tic disorder, and Tourette syndrome (TS). The prevalence of comorbid attention-deficit\/hyperactivity disorder (ADHD) was higher in moderate (21.45%) and severe (36.36%) groups than in the mild group (15.60%). The diagnosis of Tourette syndrome (aOR\u2009=\u20091.40, 95% CI: 1.23\u2013160.31), age at onset (aOR\u2009=\u20091.63, 95% CI: 1.22\u20132.18), and age at diagnosis (aOR\u2009=\u20091.63, 95% CI: 1.22\u20132.17), comorbid ADHD (aOR\u2009=\u20097.12, 95% CI: 1.39\u201336.43) were positively associated with greater tic severity. Clonidine patch (CAP) and traditional Chinese medicine (TCM) were the most common choices initial pharmacotherapy in newly diagnosed pediatric TD. Scores of YGTSS, comorbid ADHD predicted treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study contributed insights into the clinical profiles across tic severity and pharmacotherapeutic approaches in newly diagnosed pediatric TD. The findings highlighted the independent associations between baseline factors and tic severity, as well as the predictors of pharmacotherapy initiation. CAP and TCM served as the most common choices in newly diagnosed pediatric TD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1636110","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:38:34Z","timestamp":1758087514000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The clinical features and initial pharmacotherapeutic options of children with Tic disorders"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuxin","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhisheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.neurol.2025.03.011","article-title":"The diagnostic and therapeutic journey of Tourette syndrome: thematic analysis of the difficulties experienced by parents of patients","volume":"181","author":"Breton","year":"2025","journal-title":"Rev Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.psc.2024.08.008","article-title":"Pharmacotherapy for Tourette syndrome","volume":"48","author":"Jurgen","year":"2025","journal-title":"Psychiatr Clin North Am"},{"key":"B3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/mds.30084","article-title":"All-cause and cause-specific mortality in tourette syndrome and chronic tic disorder","volume":"40","author":"Fernandez de la Cruz","year":"2025","journal-title":"Mov Disord"},{"key":"B4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/15374410701279545","article-title":"Quality of life in youth with Tourette\u2019s syndrome and chronic tic disorder","volume":"36","author":"Storch","year":"2007","journal-title":"J Clin Child Adolesc Psychol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamaneurol","article-title":"Association of Tourette syndrome and chronic tic disorder with cervical spine disorders and related neurological complications","volume":"78","author":"Isung","year":"2021","journal-title":"JAMA Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.5498\/wjp.v14.i11.1641","article-title":"Family functioning mediation in tic severity and quality of life for children with Tourette syndrome","volume":"14","author":"Hu","year":"2024","journal-title":"World J Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1474-4422(22)00303-9","article-title":"Tourette syndrome: clinical features, pathophysiology, and treatment","volume":"22","author":"Johnson","year":"2023","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12888-020-03014-z","article-title":"Clinical features and neuropsychiatric comorbidities in pediatric patients with tic disorders: a retrospective chart review study from South Korea","volume":"21","author":"Park","year":"2021","journal-title":"BMC Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/mds.28593","article-title":"Is persistent motor or vocal tic disorder a milder form of Tourette syndrome?","volume":"36","author":"Claudio-Campos","year":"2021","journal-title":"Mov Disord"},{"key":"B10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.braindev.2019.02.003","article-title":"Expert consensus on pharmacotherapy for tic disorders in Japan","author":"Hamamoto","year":"2019","journal-title":"Brain Dev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1212\/WNL.0000000000007466","article-title":"Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders","author":"Pringsheim","year":"2019","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/YIC.0000000000000362","article-title":"The clinical intervention choice for pediatric tic disorder patients from a tertiary children\u2019s hospital in China: a large-scale retrospective study based on electronic medical records","volume":"36","author":"Wang","year":"2021","journal-title":"Int Clin Psychopharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"852414","DOI":"10.3389\/fphar.2022.852414","article-title":"Medication choices in children with tic disorders in Mainland China, Macao, Hong Kong, and Taiwan: perspectives of guardians and physicians","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3389\/fpsyt.2020.00774","article-title":"Current Status, diagnosis, and treatment recommendation for tic disorders in China","volume":"11","author":"Liu","year":"2020","journal-title":"Front Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.psc.2024.09.003","article-title":"Systematic literature review on public health impacts of persistent tic disorders: health care needs and health care use","volume":"48","author":"Bitsko","year":"2025","journal-title":"Psychiatr Clin North Am"},{"key":"B16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12888-021-03399-5","article-title":"Revisiting the structure of the Yale Global tic Severity Scale (YGTSS) in a sample of Chinese children with tic disorders","volume":"21","author":"Wen","year":"2021","journal-title":"BMC Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00787-021-01899-z","article-title":"European Clinical guidelines for tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment","volume":"31","author":"Roessner","year":"2022","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/mdc3.13703","article-title":"Have we forgotten what tics are? A re-exploration of tic phenomenology in youth with primary tics","volume":"10","author":"Nilles","year":"2023","journal-title":"Mov Disord Clin Pract"},{"key":"B19","doi-asserted-by":"publisher","first-page":"858","DOI":"10.4103\/aian.aian_724_23","article-title":"An update on the diagnosis and management of tic disorders","volume":"26","author":"Desai","year":"2023","journal-title":"Ann Indian Acad Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jaac.2017.01.010","article-title":"Course of Tourette syndrome and comorbidities in a large prospective clinical study","volume":"56","author":"Groth","year":"2017","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1089\/cap.2019.0050","article-title":"Population-based epidemiology of pediatric patients with treated tic disorders from real-world evidence in Korea","volume":"29","author":"Choi","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00787-011-0223-z","article-title":"Prevalence and clinical correlates of tic disorders in a community sample of school-age children","volume":"21","author":"Kraft","year":"2012","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/mds.29454","article-title":"Early-life and family risk factors for tic disorder persistence into adulthood","volume":"38","author":"Mataix-Cols","year":"2023","journal-title":"Mov Disord"},{"key":"B24","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/hbm.25683","article-title":"Brain functional and effective connectivity based on electroencephalography recordings: a review","volume":"43","author":"Cao","year":"2022","journal-title":"Hum Brain Mapp"},{"key":"B25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1684\/epd.2019.1057","article-title":"Pathophysiology of encephalopathy related to continuous spike and waves during sleep: the contribution of neuroimaging","volume":"21","author":"Siniatchkin","year":"2019","journal-title":"Epileptic Disord"},{"key":"B26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.7916\/tohm.v0.645","article-title":"Prescriptions for alpha agonists and antipsychotics in children and youth with tic disorders: a pharmacoepidemiologic study","volume":"9","author":"Cothros","year":"2019","journal-title":"Tremor Other Hyperkinet Mov"},{"key":"B27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S2352-4642(22)00316-9","article-title":"Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with tourette\u2019s syndrome: a systematic review and network meta-analysis","volume":"7","author":"Farhat","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.beth.2022.07.002","article-title":"Childhood predictors of long-term tic severity and tic impairment in Tourette\u2019s disorder","volume":"53","author":"Ricketts","year":"2022","journal-title":"Behav Ther"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1636110\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:38:35Z","timestamp":1758087515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1636110\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":28,"alternative-id":["10.3389\/fped.2025.1636110"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1636110","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"article-number":"1636110"}}